eXoZymes Inc. (EXOZ)

The past six months have seen several events impacting eXoZymes' stock. As of February 4, 2026, the company's market capitalization was $93.86 million, experiencing a 3% decrease over the past 30 days, though it increased by 2.66% over the last 12 months. The stock price has moved between a low of $8.86 and a high of $23.99 over the past year. Key events include achieving a 100x scale-up of NCT production, a third-quarter 2025 update, an analysis highlighting a need to reduce cash burn or raise capital, insights from the CEO's visit to NASDAQ headquarters, advancing commercial readiness with production metrics on an initial NCT pilot run, an interview with the CEO by Nasdaq, and a 5.5% increase in shares.

The provided information does not explicitly detail any demand seasonality for eXoZymes, Inc.'s products and services. The company's focus suggests that demand might be relatively stable, driven by ongoing industrial, health, and energy needs rather than significant seasonal fluctuations. However, without specific data, any seasonality remains unconfirmed.

eXoZymes, Inc., formerly Invizyne Technologies, Inc., is a biotechnology company specializing in cell-free biomanufacturing, operating within the Health Care sector. The company has developed a proprietary technology that combines enzymes with artificial intelligence to create advanced enzymes engineered to function outside of living cells. This platform transforms biomass and sustainable feedstocks into valuable small-molecule chemicals, medicines, and fuels. The company's products include Active Pharmaceutical Ingredients (APIs), nutraceuticals, biofuels, essential chemicals, NCT, non-intoxicating cannabinoids, santalene, enzyme modules and cell-free exozyme biosolutions, and magnetic bead-based nucleic acid extraction kits.

eXoZymes, Inc. is headquartered in Monrovia, California, USA. The company's mission suggests a global market ambition for its sustainable and eco-friendly alternatives to traditional chemical production methods.

eXoZymes has actively worked on building its brand reputation over the past year. The company changed its name from Invizyne Technologies, Inc. to eXoZymes, Inc. in February 2025. In April 2025, eXoZymes was featured on the cover of GEN Biotechnology with a paper introducing the term "exozymes". In April 2025, eXoZymes launched BioClick, an enzyme engineering technology supported by a $300K NIH grant. CEO Michael Heltzen has participated in interviews with various media outlets. The company's technology has been validated through publications in prestigious journals. Mohammad Hayat resigned from the Board of Directors, President, and Chairman roles, and Edgardo Rayo was appointed to the Board, with Christopher A. Marlett becoming the new Chairman.

Insider ownership of eXoZymes, Inc. is substantial, with 72.41% of the stock held by insiders. Christopher A. Marlett and Anthony Digiandomenico each own 45.41% of the company. Michael Heltzen, the President & CEO, has made several insider purchases. Paul Opgenorth, the Co-Founder & Vice President of Development, purchased shares on November 19, 2024. Institutional holdings are comparatively smaller.